Michael Klein Appointed President and CEO of Xoft, a Private Medical Technologies Company Focusing on Breast Cancer Treatment

Xoft’s Axxent(TM) Electronic Brachytherapy System to Be Exhibited at the National Breast Cancer Symposium in San Antonio

FREMONT, CA -- 12/08/2004 -- Michael S. Klein has been appointed President and CEO of Xoft, a private medical technology company developing treatment systems for radiation oncology. He has also joined the Board of Directors. Klein joins Xoft after serving as President and CEO of R2 Technology for 4 years until earlier this year. During his time at the company, R2 developed and commercialized computer-aided detection systems for breast cancer and other diseases, which grew from $5 million to over $50 million in annual revenue in annual revenue. Previously, Klein served as General Manager of Varian’s Medical Systems Oncology business where he managed several business units ranging in sales from $20 million to $200 million.

“Mike’s unique experience in both breast care and radiation oncology makes him a superior choice to lead Xoft into the commercialization phase of it’s breakthrough ’electronic brachytherapy system,’” according to Jeff Bird of Sutter Hill Ventures, a member of the Board of Directors at Xoft. “In all of his prior assignments Mike was able to accelerate the adoption rate of novel technologies and create market leading positions.”

“Radiation Oncologists are going to be offered remarkable new treatment solutions over the next 10 years and I believe that ’electronic brachytherapy’ will be at the forefront of those important new tools for treating many cancers, including breast cancer,” said Michael Klein.

Klein served as Vice President, Sales and Marketing and subsequently as General Manager of the Oncology Systems Group of Varian Medical Systems, Inc. from 1997 to 2000. From 1990 to 1997, Klein served in a series of senior management positions at Becton Dickinson and Company, the last of which was Vice President of Sales and Marketing for BD Medical’s North American Sales & Marketing Group. Before that, Klein held various sales, marketing, planning and business development positions with several major corporations Klein received an M.B.A. from the New York Institute of Technology and a B.A. in history and education from the State University of New York, Albany.

About Xoft

Xoft is developing leading-edge new technologies for the practice of radiation oncology through electronic brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent Electronic Brachytherapy System, Xoft’s first treatment system, is designed for use in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Xoft is exhibiting the Axxent Electronic Brachytherapy System at the San Antonio Breast Cancer Symposium in San Antonio, Texas from December 8-11, 2004.

The Xoft Axxent™ Electronic Brachytherapy System is for investigational use only. FDA clearance and CE Mark are pending.

Contact Information

Cece Lee

N/A

Blanc & Otus Public Relations

Contact via E-mail